共被期刊论文引用了4次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells显示文摘In the last years,several studies have been focused on elucidate the role of tumor microenvironment(TME)in cancer development and progression.Within TME,cells from adaptive and innate immune system are one of the main abundant components.The dynamic interactions between immune and cancer cells lead to the activation of complex molecular mechanisms that sustain tumor growth.This important cross-talk has been elucidate for several kind of tumors and occurs also in patients with liver cancer,such as hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma(iCCA).Liver is well-known to be an important immunological organ with unique microenvironment.Here,in normal conditions,the rich immune-infiltrating cells cooperate with non-parenchymal cells,such as liver sinusoidal endothelial cells and Kupffer cells,favoring self-tolerance against gut antigens.The presence of underling liver immunosuppressive microenvironment highlights the importance to dissect the interaction between HCC and iCCA cells with immune infiltrating cells,in order to understand how this cross-talk promotes tumor growth.Deeper attention is,in fact,focused on immune-based therapy for these tumors,as promising approach to counteract the intrinsic anti-tumor activity of this microenvironment.In this review,we will examine the key pathways underlying TME cell-cell communications,with deeper focus on the role of natural killer cells in primary liver tumors,such as HCC and iCCA,as new opportunities for immune-based therapeutic strategies. | Michela Anna Polidoro Joanna Mikulak Valentina Cazzetta Ana Lleo Domenico Mavilio Guido Torzilli Matteo Donadon | 2020 | World Journal of Gastroenterology2020，26，33： | 4 |
| 2 | 索拉非尼的心血管不良反应及机制的研究进展显示文摘索拉非尼是一种多酪氨酸激酶抑制剂,对多种参与血管生成、肿瘤生长和肿瘤转移的酪氨酸激酶受体具有靶向活性,目前被广泛用于肾细胞癌、肝细胞癌的治疗。索拉非尼延长了许多恶性肿瘤患者的生命,但是其药物不良反应尤其是心血管方面的严重不良反应仍影响患者的临床获益。因此,防止或减少索拉非尼产生的心血管不良反应至关重要。本文就索拉非尼引起的心血管不良反应及可能的机制进行综述。 | 凌静 张青海 郑昭芬 | 2021 | 中国临床药理学与治疗学2021，26，11： | 1 |
| 3 | 胆红素上调PPARα/CPT1A降低Huh7细胞对索拉非尼的敏感性显示文摘目的观察胆红素(bilirubin,Bil)对索拉非尼(sorafenib,Sor)治疗肝癌效果的影响,并探讨其可能机制。方法体外实验:用不同浓度的Sor(0、2、4、8、16、32μmol/L)、Bil(0、2.5、5、10、20、40μmol/L)及不同浓度Sor+Bil(20μmol/L)培养Huh7细胞系不同时间(24、48、72 h)后,通过CCK-8法检测细胞活力。采用Sor(4μmol/L)、Bil(20μmol/L)、Sor(4μmol/L)+Bil(20μmol/L)处理Huh7细胞,48 h后用流式细胞仪检测细胞周期,14 d后通过克隆形成实验检测药物对细胞增殖的影响。体内实验:取16只裸鼠构建Huh7细胞异种移植瘤模型,按S型抽样方法将裸鼠分为Con组、Bil组(25 mg·kg^(-1)·d^(-1))、Sor(15 mg·kg^(-1)·d^(-1))组、Bil(25 mg·kg^(-1)·d^(-1))+Sor(15 mg·kg^(-1)·d^(-1))组,每组各4只,并进行相应处理。通过Western blot和实时荧光定量PCR(RT-qPCR)检测各组过氧化物酶体增殖物激活受体(peroxisome proliferator-activated receptor,PPARα)、肉毒碱棕榈酰基转移酶1A(carnitine palmityl transferase 1A,CPT1A)的表达量。加入CPT1A抑制剂乙莫克舍(etomoxir,Eto)后,通过CCK-8、克隆形成实验验证Bil削弱Sor对肝癌细胞的增殖抑制与PPARα/CPT1A的相关性。结果CCK-8结果显示,Sor对Huh7细胞的增殖抑制效应呈现剂量和时间依赖(P<0.05),Bil对Huh7细胞活力没有明显影响(P>0.05)。与单独Sor处理组相比,Bil+Sor组细胞增殖活力增加,细胞克隆数目较多(P<0.05),细胞在S期的数目减少(P<0.05)。体内实验结果显示:Sor组肿瘤体积和质量小于Con组(P<0.05),Bil+Sor组肿瘤体积和质量大于Sor组(P<0.05)。Western blot和RT-qPCR结果显示:与Sor组相比,Bil+Sor组PPARα、CPT1A的表达增多(P<0.05)。与Bil+Sor组相比,加入Eto后,Bil+Sor+Eto组细胞增殖活力降低(P<0.05),细胞克隆数目减少(P<0.05)。结论胆红素通过PPARα/CPT1A介导脂肪酸氧化削弱索拉非尼的抗肿瘤效果。 | 谭君 张弛 董严 梁后杰 | 2022 | 陆军军医大学学报2022，44，16： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员